Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAventyn, Inc.
About this trial
Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.
Eligibility criteria
Qualifiers
None
Disqualifiers
Study informed consent will be obtained before enrollment in the study for Phase 1 and Phase 2
All subjects 18 years or above will be a criteria for inclusion for Phase 1
For Phase 2, men and women 50 years or older with positive Covid19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in the intervention arm of the study;
For phase 2, subjects should be able to be randomized within 48 hours of Covid19 antigen positive status
Trial design
Treatments tested in this trial
- COMPASSION Digital Biomarker
Treatment groups
1,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Aventyn, Inc.
Lead sponsor
TwinEpidemic
Collaborator
Arizona State University
Collaborator
Intel Corporation
Collaborator
Heart Health Organization East Valley
Collaborator
Source ClinicalTrials.gov